依帕司他联合甲钴胺片治疗糖尿病周围神经病变的效果

Abstract
Figure/Table
References (20)
Related Citation (2)

Download: PDF (518 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the efficacy of Epalrestat combined with Mecobalamin Tablets on patients with diabetic peripheral neuropathy (DPN). Methods Ninety-four patients with DPN treated in Nanchong Second People′s Hospital of SichuanProvince from June 2016 to June 2017 were selected. According to the random number table method, the patients were divided into the control group and the combined group, with 47 cases in each group. The control group was treated with Mecobalamin Tablets, 0.5-1.0 mg/time and 3 times/d, and the combined group was treated with Epalrestat on the basis of the control group, 50 mg/time, and 3 times/d. The two groups were treated for 8 weeks. The clinical efficacy, the changes of interleukin-1β (IL-1β) and matrix metalloproteinase 9 (MMP-9) levels before and after treatment and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the combined group was 91.49%, which was significantly higher than that of the control group (72.34%) (P ＜ 0.05). After treatment, nerve conduction velocity in the two groups increased significantly in comparison of those before treatment, and the level in the combined group was significantly higher than that in the control group (P ＜ 0.05). The levels of IL-1β and MMP-9 in the two groups were significantly lower than those before treatment, and the levels of IL-1β and MMP-9 in the combined group were significantly lower than those in the control group (all P ＜ 0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (P ＞ 0.05). Conclusion The application of Epalrestat in patients with DPN has good therapeutic effect, which can effectively regulate the expression of IL-1β and MMP-9. And it can obviously reduce the level of serum inflammatory mediators, effectively slow down the rogression of the disease, and can enhance the clinical effect, so it has better clinical value.

Key words： Diabetic peripheral neuropathy Epalrestat Interleukin-1β Matrix etalloproteinase-9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Yingying1 LI Lixia1 HE Su1 LONG Shiyu2

Cite this article:

HUANG Yingying1 LI Lixia1 HE Su1 LONG Shiyu2. Efficacy of Epalrestat combined with Mecobalamin Tablets in the treatment of diabetic peripheral neuropathy[J]. 中国医药导报, 2018, 15(20): 63-66.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I20/63

[1] Wang X， Lin H， Xu S，et al. The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy：Protocol for a systematic review and meta-analysis [J]. Medicine，2018，97（6）：e9828.
[2] 傅明捷，何明坤，王艳，等.甲钴胺联合依帕司他治疗老年糖尿病周围神经病变42例[J].中国老年学杂志，2013， 33（8）：1892-1893.
[3] Matsumoto C，Petrone AB，Sesso HD，et al. Chocolate consumption and risk of diabetes mellitus in the Physicians' Health Study [J]. Am J ClinNutr，2015，101（2）：362-367.
[4] 胡仁明，樊东升.糖尿病周围神经病变诊疗规范（征求意见稿）[J].中国糖尿病杂志，2009，17（8）：638-640.
[5] 李平，马建华，高佳麟，等.依帕司他治疗糖尿病周围神经病变安全性和有效性的随机、对照、多中心临床研究[J].中华内分泌代谢杂志，2015，15（9）：743-747.
[6] 张青立.依帕司他对糖尿病周围神经病变患者炎性因子的影响[J].中国实用神经疾病杂志，2016，19（22）：39-41.
[7] Villena JE. Diabetes mellitus in Peru [J]. Ann Global Health，2015，81（6）：765-775.
[8] 许学忠，穆攀伟，王曼曼，等.血栓通注射液联合依帕司他和甲钴胺注射液治疗糖尿病周围神经病变的疗效观察[J].现代药物与临床，2016，31（4）：479-482.
[9] 王杨，刘畅.依帕司他治疗糖尿病周围神经病变的疗效及机制[J].中国老年学杂志，2015，35（1）：93-95.
[10] 韦丽，张建军.甲钴胺、依帕司他、马来酸桂哌齐特治疗糖尿病周围神经病变的效果[J].中国医药导报，2016， 13（5）：157-160.
[11] 陈鹤鸣，张晓军，陈浩，等.依帕司他治疗糖尿病神经病变下肢溃疡的效果[J].中国医药导报，2016，13（15）：150-153.
[12] Ramos AR，Wallace DM，Pandiperumal SR，et al. Associations between sleep disturbances and diabetes mellitus among blacks with metabolic syndrome：Results from the Metabolic Syndrome Outcome Study （MetSO）[J]. Ann Med，2015，47（3）：1-5.
[13] 刘香兰.依帕司他联合甲钴胺对糖尿病周围神经病变患者生存质量的影响[J].中国基层医药，2017，24（11）：1623-1626.
[14] Noctor E，Crowe C，Carmody LA，et al. ATLANTIC-DIP：prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria [J]. Acta Diabetol，2015，52（1）：153-160.
[15] Tilg H，Moschen AR，Roden M. NAFLD and diabetes mellitus [J]. Nat Rev Gastroenterol Hepatol，2017，14（1）：32.
[16] 衡爱玲.依帕司他联合甲钴胺治疗糖尿病周围神经病变的临床疗效[J].临床医学研究与实践，2018，3（3）：29-31.
[17] 王立娜，杜娟，闻梓钧，等.木丹颗粒联合依帕司他治疗糖尿病周围神经病变疗效观察[J].辽宁中医杂志，2016， 43（9）：1890-1891.
[18] 侯静雯，侯志梅，王娜，等.依帕司他联合甲钴胺治疗老年2型糖尿病周围神经病变的疗效[J].医学综述，2017， 23（5）：1013-1017.
[19] 赖鸿鹄.依帕司他联合甲钴胺治疗2型糖尿病周围神经病变疗效观察[J].吉林医学，2012，33（19）：4130-4131.
[20] 孙殿静，谷巍，刘晴晴.依帕司他联合硫辛酸治疗糖尿病周围神经病变的临床观察[J].中国药房，2017，28（23）：3226-3229.